• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Democrats Use Health Law to Assail Republicans

Article

A little-noticed provision of the new health care law is causing big headaches for some members of Congress in this year’s elections. And it is likely to cause even bigger headaches for lawmakers next year.

The provision, written into the law at the behest of a Republican senator, says members of Congress must get their health benefits through new insurance exchanges being established in every state.

Read the full story: http://nyti.ms/VjekEk

Source: The New York Times

Related Videos
Video 2 - "Adverse Events & Existing Treatment Options for Dry Eye Disease"
Overview of Dry Eye Disease (DED) Causes and Treatments
Video 12 - "Harnessing Indication-Specific Data on Biosimilars"
Related Content
Contributor: Reflections on World AIDS Day 2023—A Call to Increase Research Funding on HIV and Aging

Contributor: Reflections on World AIDS Day 2023—A Call to Increase Research Funding on HIV and Aging

December 1st 2023
Article

Research on HIV and aging should be the focus of future research as World AIDS Day brings the chronic illness to the forefront.

Read More

Managed Care Cost podcast logo on white background

Managed Care Cast Presents: Insights Into Precision Medicine in NSCLC

November 30th 2023
Podcast

In this podcast, a trio of experts discuss precision medicine in non–small cell lung cancer (NSCLC), current immunotherapies, and more.

Listen

Vitamin D | Image credit: Cozine – stock.adobe.com

Vitamin D Linked to Clinical, Endoscopic Outcomes of Vedolizumab Treatment for IBD

November 30th 2023
Article

Pretreatment vitamin D levels were associated with endoscopic improvement in patients with ulcerative colitis and decreased C-reactive protein levels in patients with Crohn disease.

Read More

Managed Care Cast Presents: Opportunities for Adalimumab Biosimilars, Part 2

Managed Care Cast Presents: Opportunities for Adalimumab Biosimilars, Part 2

November 21st 2023
Podcast

In part 2 of this 2-part podcast, a panel of experts discusses implementation biosimilars in biologic-naïve patients, auto-substitution, and more.

Listen

Site Logo

Managing Lupus Nephritis: From Clinical and Economic Implications to Diagnosis and Treatment Advances

November 30th 2023
Article

Read More

Psoriasis skin, eczema, rash and other skin diseases. A woman hides her face, she is ashamed of her autoimmune genetic disease. Imperfect beauty. | Image credit: stockmaster - stock.adobe.com.jpg

Bimekizumab-bkzx, the Newest Psoriasis Treatment, Is Now Available

November 30th 2023
Article

Bimekizumab-bkzx (Bimzelx) is the first dual interleukin 17A (IL-17A) and interleukin 17F (IL-17F) inhibitor to treat moderate-to-severe plaque psoriasis. It launches with a list price of $7200 per syringe.

Read More

© 2023 MJH Life Sciences
AJMC®
All rights reserved.